Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | IMW 2021: MRD highlights

Daniel Auclair • 11 Sep 2021
IMW 2021
Multiple Myeloma

Daniel Auclair, PhD, of the Multiple Myeloma Research Foundation (MMRF), Norwalk, CT, gives an overview of the key updates on the use of measurable residual disease (MRD) in myeloma, as presented at the IMW 2021 meeting, and discusses updates and sessions which will take place at the upcoming MMRF MRD Meeting on October 13th. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

More from Daniel Auclair

5:24
Novel immunotherapies for multiple myeloma
Daniel Auclair • 8 Apr 2021
5:59
myDRUG: precision medicine in multiple myeloma
Daniel Auclair • 8 Apr 2021
5:58
What’s to come for the MMRF in 2021?
Daniel Auclair • 15 Dec 2020
2:04
How has COVID-19 affected the myeloma field?
Daniel Auclair • 15 Dec 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals